Merck & Co Extending Allergy Interests With House Dust Mite Filing

Merck & Co has submitted a BLA for what is likely to be its third sublingual allergy immunotherapy (SLIT) tablet to become available in the US, one developed to treat house dust mite (HDM) allergies, an important cause of allergic rhinitis and allergic asthma that might boost so-far underwhelming US sales of its new allergy products.

Merck & Co has submitted a BLA for what is likely to be its third sublingual allergy immunotherapy (SLIT) tablet to become available in the US, one developed to treat house dust mite (HDM) allergies, an important cause of allergic rhinitis and allergic asthma that might boost so-far underwhelming US sales of its new allergy products.

The US allergy vaccines market is dominated by old-school injectable allergen extracts that allergy specialists formulate in their offices and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

More from Therapy Areas

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By 

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.